Navigation Links
Shire plc - Statement re ProAmatine
Date:8/17/2010

Shire plc - Statement re ProAmatine -- PHILADELPHIA, Pennsylvania, August 17, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Acquisitions, Mergers and Takeovers, Clinical Trials & Medical Discoveries, FDA Approval Click to view news release full screen  

Shire plc - Statement re ProAmatine

 

PHILADELPHIA, Pennsylvania, August 17, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) acquired ProAmatine as a part of the acquisition of Roberts Pharma in 1999 and Shire conducted and completed the post marketing trials that the FDA required. The FDA, however, viewed these trials as inconclusive and required that additional trials be conducted for ProAmatine to maintain its marketing authorization. As a result, Shire elected to withdraw the product effective September 30, 2010 and notified the FDA in November 2009 and healthcare professionals earlier this year of this decision. Shire's withdrawal of the NDA was not related to any concerns regarding the safety of ProAmatine.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

For further information please contact: Media Matthew Cabrey (mcabrey@shire.com) +1-610-613-2790 Ben Atwell (Ben.Atwell@fd.com) +44-020-7269-7242
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
2. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
3. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
4. Shire plc Appoints Two New Board Directors
5. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
6. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
7. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
8. Shires Replenished Portfolio Drives Excellent Quarterly Performance
9. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
10. Shire Supports Rare Disease Day 2010
11. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/15/2017)... (PRWEB) , ... February 15, 2017 , ... ... Posard, as President and Chief Commercial Officer with GenePeeks. Matt is a ... , GenePeeks is a computational genomics company focused on identifying inherited disease risk ...
(Date:2/15/2017)... WASHINGTON, Feb. 15, 2017  Vanda Pharmaceuticals Inc. ... results for the fourth quarter and full year ... an exceptional year for Vanda as we continued ... and secured long-term exclusivity for Fanapt," said Mihael ... addition, our emerging pipeline with important 2017 milestones ...
(Date:2/15/2017)... ... February 15, 2017 , ... Diameter Health (Diameter) ... Health technology in the hands of Lantana analysts. The high-performance platform of Diameter ... public health entities – all those mining value from clinical data – to ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
Breaking Biology News(10 mins):